227 related articles for article (PubMed ID: 19259602)
1. Lipid based nanovectors containing ruthenium complexes: a potential route in cancer therapy.
Vaccaro M; Del Litto R; Mangiapia G; Carnerup AM; D'Errico G; Ruffo F; Paduano L
Chem Commun (Camb); 2009 Mar; (11):1404-6. PubMed ID: 19259602
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium-based complex nanocarriers for cancer therapy.
Mangiapia G; D'Errico G; Simeone L; Irace C; Radulescu A; Di Pascale A; Colonna A; Montesarchio D; Paduano L
Biomaterials; 2012 May; 33(14):3770-82. PubMed ID: 22357152
[TBL] [Abstract][Full Text] [Related]
3. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
4. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.
Yan YK; Melchart M; Habtemariam A; Sadler PJ
Chem Commun (Camb); 2005 Oct; (38):4764-76. PubMed ID: 16193110
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium(II)-arene complexes with strong fluorescence: insight into the underlying mechanism.
Zhou Q; Lei W; Chen Y; Li C; Hou Y; Zhang B; Wang X
Chemistry; 2012 Jul; 18(28):8617-21. PubMed ID: 22700010
[No Abstract] [Full Text] [Related]
6. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
7. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
8. In silico evolution of substrate selectivity: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin.
Deubel DV; Lau JK
Chem Commun (Camb); 2006 Jun; (23):2451-3. PubMed ID: 16758012
[TBL] [Abstract][Full Text] [Related]
9. Anticancer cationic ruthenium nanovectors: from rational molecular design to cellular uptake and bioactivity.
Mangiapia G; Vitiello G; Irace C; Santamaria R; Colonna A; Angelico R; Radulescu A; D'Errico G; Montesarchio D; Paduano L
Biomacromolecules; 2013 Aug; 14(8):2549-60. PubMed ID: 23705931
[TBL] [Abstract][Full Text] [Related]
10. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.
Hu W; Luo Q; Ma X; Wu K; Liu J; Chen Y; Xiong S; Wang J; Sadler PJ; Wang F
Chemistry; 2009 Jul; 15(27):6586-94. PubMed ID: 19533706
[TBL] [Abstract][Full Text] [Related]
11. Organometallic ruthenium and osmium compounds of pyridin-2- and -4-ones as potential anticancer agents.
Henke H; Kandioller W; Hanif M; Keppler BK; Hartinger CG
Chem Biodivers; 2012 Sep; 9(9):1718-27. PubMed ID: 22976964
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol-based nucleolipid-ruthenium complex stabilized by lipid aggregates for antineoplastic therapy.
Simeone L; Mangiapia G; Vitiello G; Irace C; Colonna A; Ortona O; Montesarchio D; Paduano L
Bioconjug Chem; 2012 Apr; 23(4):758-70. PubMed ID: 22369596
[TBL] [Abstract][Full Text] [Related]
13. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
Bergamo A; Gaiddon C; Schellens JH; Beijnen JH; Sava G
J Inorg Biochem; 2012 Jan; 106(1):90-9. PubMed ID: 22112845
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex.
Herman A; Tanski JM; Tibbetts MF; Anderson CM
Inorg Chem; 2008 Jan; 47(1):274-80. PubMed ID: 18062685
[TBL] [Abstract][Full Text] [Related]
15. Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers.
Li L; Wong YS; Chen T; Fan C; Zheng W
Dalton Trans; 2012 Jan; 41(4):1138-41. PubMed ID: 22159211
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium complexes can target determinants of tumour malignancy.
Bergamo A; Sava G
Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
[TBL] [Abstract][Full Text] [Related]
17. 2,2':6',2''-Terpyridine meets 2,6-bis(1H-1,2,3-triazol-4-yl)pyridine: tuning the electro-optical properties of ruthenium(II) complexes.
Schulze B; Friebe C; Hager MD; Winter A; Hoogenboom R; Görls H; Schubert US
Dalton Trans; 2009 Feb; (5):787-94. PubMed ID: 19156271
[TBL] [Abstract][Full Text] [Related]
18. Ru(III)-based compounds with sulfur donor ligands: synthesis, characterization, electrochemical behaviour and anticancer activity.
Giovagnini L; Sitran S; Castagliuolo I; Brun P; Corsini M; Zanello P; Zoleo A; Maniero A; Biondi B; Fregona D
Dalton Trans; 2008 Dec; (47):6699-708. PubMed ID: 19153618
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium porphyrin compounds for photodynamic therapy of cancer.
Schmitt F; Govindaswamy P; Süss-Fink G; Ang WH; Dyson PJ; Juillerat-Jeanneret L; Therrien B
J Med Chem; 2008 Mar; 51(6):1811-6. PubMed ID: 18298056
[TBL] [Abstract][Full Text] [Related]
20. Size controlled formation of silver nanoparticles by direct bonding of ruthenium complexes bearing a terminal mono- or bi-pyridyl group.
Mayer CR; Dumas E; Sécheresse F
Chem Commun (Camb); 2005 Jan; (3):345-7. PubMed ID: 15645032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
